Research Project
10132064
Project Summary/Abstract Our parent grant (AT010138) aimed to explore brain mechanisms of a novel body-mind intervention (IBMT) in adults with substance use, and to examine intervention effects on attention/cognition, emotion, self-control and behavior change using psychosocial and neuroimaging methods. In our series of RCTs, the evidence-based intervention IBMT has been shown to reduce stress, improve attention/cognition, emotion, self-control and quality of life in healthy young and older adults. These findings may suggest the potential intervention effects of IBMT in improving cognitive function, health and well-being for aging population with self-reported memory or cognitive complaints or already at risk for cognitive decline and related disorders such as mild cognitive impairment (MCI) and Alzheimer?s disease and related dementia (ADRD). Subjective cognitive decline (SCD) is the self-reported perception of memory or cognitive problems, which has recently received increasing attention as a risk factor for the development of objective cognitive decline such as MCI and ADRD. However, it remains largely unexplored whether available preventions and treatments may have efficacy on SCD, MCI and/or ADRD. Consistent with the goal of this Alzheimer?s-focused administrative supplements for NIH grants that are not focused on AD (PA-18-591), this supplement aims to apply the same RCT design, intervention IBMT and psychosocial and neuroimaging measurements to explore 1) whether IBMT could improve attention/cognition, emotion, self-control and quality of life in older adults (>60 years old) with SCD, and 2) the underlying brain mechanisms associated with SCD improvements as compared to an active control intervention - relaxation training (RT). This supplement is a natural ADRD-relevant extension of our parent intervention RCT and the preliminary results of the pilot project could provide evidence on potential intervention effectiveness and its underlying brain mechanisms, which could inform future development of evidence-based interventions targeting SCD, MCI and ADRD through full R01 clinical trials.
